FAQ on the New Chapter 2.1.7 of the European Pharmacopoeia

On January 1st, 2022, the new Chapter 2.1.7, published by the European Pharmacopoeia (Ph.Eur.) and pertaining to balances used for analytical purposes, became effective. The Ph.Eur. is the legally binding reference for all pharmaceutical companies placing pharmaceutical products in the market of European member states.

Download this guide to discover the answers to these commonly asked questions about Ph.Eur. compliance:

What are the requirements of Chapter 2.1.7 concerning the calibration of a balance?
What are the requirements on repeatability and sensitivity?
How often should performance checks be conducted?
How does the Cubis® II laboratory balance support compliance with Chapter 2.1.7?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

This content is copyright protected. Any public or private use of this content is subject to prevailing copyright laws. Please contact Technology Networks for permission requests.